An economic evaluation of vagus nerve stimulation as an adjunctive treatment to anti-seizure medications for the treatment of drug-resistant epilepsy in England

References

• World Health Organisation. Health topics: epilepsy; 2019. Available from: https://www.who.int/health-topics/epilepsy
   Google Scholar
• Beghi E. The epidemiology of epilepsy. Neuroepidemiology. 2020;54(2):185–191.
   PubMed Web of Science ®Google Scholar
• Karakis I, Cole AJ, Montouris GD, et al. Caregiver burden in epilepsy: determinants and impact. Epilepsy Res Treat. 2014;2014:808421.
   PubMedGoogle Scholar
• National Institute for Health and Care Excellence. Epilepsies: diagnosis and management (CG137); 2012. Available from: https://www.nice.org.uk/guidance/cg137/chapter/1-Guidance#vagus-nerve-stimulation-vns
   Google Scholar
• Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc task force of the ILAE commission on therapeutic strategies. Epilepsia. 2010;51(6):1069–1077.
   PubMed Web of Science ®Google Scholar
• Hauser WA, Beghi E. First seizure definitions and worldwide incidence and mortality. Epilepsia. 2008;49(Suppl 1):8–12.
   PubMed Web of Science ®Google Scholar
• Meeraus WH, Petersen I, Chin RF, et al. Childhood epilepsy recorded in primary care in the UK. Arch Dis Child. 2013;98(3):195–202.
   PubMed Web of Science ®Google Scholar
• Mohanraj R, Brodie MJ. Diagnosing refractory epilepsy: response to sequential treatment schedules. Eur J Neurol. 2006;13(3):277–282.
   PubMed Web of Science ®Google Scholar
• Neligan A, Bell GS, Johnson AL, et al. The long-term risk of premature mortality in people with epilepsy. Brain. 2011;134(Pt 2):388–395.
   PubMed Web of Science ®Google Scholar
• Platt M, Sperling MR. A comparison of surgical and medical costs for refractory epilepsy. Epilepsia. 2002;43(Suppl 4):25–31.
   PubMed Web of Science ®Google Scholar
• Dalic L, Cook MJ. Managing drug-resistant epilepsy: challenges and solutions. Neuropsychiatr Dis Treat. 2016;12:2605–2616.
   PubMed Web of Science ®Google Scholar
• Strzelczyk A, Griebel C, Lux W, et al. The burden of severely drug-refractory epilepsy: a comparative longitudinal evaluation of mortality, morbidity, resource use, and cost using German health insurance data. Front Neurol. 2017;8:712.
   Google Scholar
• Villanueva V, Girón JM, Martín J, et al. Quality of life and economic impact of refractory epilepsy in Spain: the ESPERA study. Neurología. 2013;28(4):195–204.
   PubMed Web of Science ®Google Scholar
• Garcia ME, Garcia-Morales I, Gil-Nagel A. Prevalence of depressive symptoms and their impact on quality of life in patients with drug-resistant focal epilepsy (IMDYVA study). Epilepsy Res. 2015;110:157–165.
   Google Scholar
• LivaNova. Data on file, personal communications; 2021.
   Google Scholar
• Morris GL, Gloss D, Buchhalter J, et al. Evidence-based guideline update: vagus nerve stimulation for the treatment of epilepsy: report of the guideline development subcommittee of the American Academy of Neurology. Epilepsy Curr. 2013;13(6):297–303.
   PubMed Web of Science ®Google Scholar
• Shaw BK, Robalino S, King V, et al. Vagal nerve stimulation for epilepsy and depression: final evidence report. Center for Evidence-based Policy, Oregon Health & Science University; 2020. Available from: https://www.hca.wa.gov/assets/program/vns-final-rpt-complete-20200520.pdf
   Google Scholar
• Aburahma SK, Alzoubi FQ, Hammouri HM, et al. Vagus nerve stimulation therapy in a developing country: a long term follow up study and cost utility analysis. Seizure. 2015;25:167–172.
   PubMed Web of Science ®Google Scholar
• Forbes R. Cost-utility of vagus nerve stimulation (VNS) therapy for medically refractory epilepsy-an update. Seizure. 2008;17(4):387–388.
   PubMed Web of Science ®Google Scholar
• Forbes RB, Macdonald S, Eljamel SAM, et al. Cost-utility analysis of vagus nerve stimulators for adults with medically refractory epilepsy. Seizure. 2003;12(5):249–256.
   PubMed Web of Science ®Google Scholar
• Manjunath R, Paradis PE, Parisé H, et al. Burden of uncontrolled epilepsy in patients requiring an emergency room visit or hospitalisation. Neurology. 2012;79(18):1908–1915.
   PubMed Web of Science ®Google Scholar
• Messori A, Trippoli S, Becagli P, et al. Adjunctive lamotrigine therapy in patients with refractory seizures: a lifetime cost-utility analysis. Eur J Clin Pharmacol. 1998;53(6):421–427.
   PubMed Web of Science ®Google Scholar
• Mulhern B, Pink J, Rowen D, et al. Comparing generic and condition-specific preference-based measures in epilepsy: EQ-5D-3L and NEWQOL-6D. Value Health. 2017;20(4):687–693.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Guide to the methods of technology appraisal; 2013. Available from: https://www.nice.org.uk/process/pmg9/resources/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781
   Google Scholar
• Handforth A, DeGiorgio CM, Schachter SC, et al. Vagus nerve stimulation therapy for partial-onset seizures: a randomized active-control trial. Neurology. 1998;51(1):48–55.
   PubMed Web of Science ®Google Scholar
• The vagus nerve stimulation study group. A randomized controlled trial of chronic vague nerve stimulation for treatment of medically intractable seizures. Neurology. 1995;45:224–230.
   PubMed Web of Science ®Google Scholar
• LivaNova. Patient level seizure data for randomised controlled trials E03 (1995) and E05 (1998). Data provided by LivaNova PLC on 10 September 2020; 2020.
   Google Scholar
• Ara R, Brazier JE. Populating an economic model with health state utility values: moving toward better practice. Value Health. 2010;13(5):509–518.
   PubMed Web of Science ®Google Scholar
• Ara R, Brazier JE. Using health state utility values from the general population to approximate baselines in decision analytic models when condition-specific data are not available. Value Health. 2011;14(4):539–545.
   PubMed Web of Science ®Google Scholar
• Bolin K, Berggren F, Forsgren L. Lacosamide as treatment of epileptic seizures – cost utility results for Sweden. Acta Neurol Scand. 2010;121(6):406–412.
   PubMed Web of Science ®Google Scholar
• Kristian B, Wachtmeister K, Stefan F, et al. Retigabine as add-on treatment of refractory epilepsy-a cost-utility study in a Swedish setting. Acta Neurol Scand. 2013;127(6):419–426.
   PubMed Web of Science ®Google Scholar
• Englot DJ, Rolston JD, Wright CW, et al. Rates and predictors of seizure freedom with vagus nerve stimulation for intractable epilepsy. Neurosurgery. 2016;79(3):345–353.
   PubMed Web of Science ®Google Scholar
• Morris GL, 3rd, Mueller WM. Long-term treatment with vagus nerve stimulation in patients with refractory epilepsy. The vagus nerve stimulation study group E01–E05. Neurology. 1999;53(8):1731–1735.
   PubMed Web of Science ®Google Scholar
• Camp C, Smithson WH, Bunker MT, et al. Impact of vague nerve stimulation on secondary care burden in children and adults with epilepsy: review of routinely collected hospital data in England. Epilepsy Behav. 2015;52:68–73.
   PubMed Web of Science ®Google Scholar
• Horowitz G, Amit M, Fried I, et al. Vagal nerve stimulation for refractory epilepsy: the surgical procedure and complications in 100 implantations by a single medical center. Eur Arch Otorhinolaryngol. 2013;270(1):355–358.
   PubMed Web of Science ®Google Scholar
• Selner AN, Rosinski CL, Chiu RG, et al. Vagal nerve stimulation for epilepsy in adults: a database risk analysis and review of the literature. World Neurosurg. 2019;121:e947–e953.
   PubMed Web of Science ®Google Scholar
• Tatum WO, Johnson KD, Goff S, et al. Vagus nerve stimulation and drug reduction. Neurology. 2001;56(4):561–563.
   PubMed Web of Science ®Google Scholar
• Vale FL, Ahmadian A, Youssef AS, et al. Long-term outcome of vagus nerve stimulation therapy after failed epilepsy surgery. Seizure. 2011;20(3):244–248.
   PubMed Web of Science ®Google Scholar
• Selai CE, Trimble MR, Price MJ, et al. Evaluation of health status in epilepsy using the EQ-5D questionnaire: a prospective, observational, 6-month study of adjunctive therapy with anti-epileptic drugs. Curr Med Res Opin. 2005;21(5):733–739.
   PubMed Web of Science ®Google Scholar
• Doyle S, Lloyd A, Walker M. Health state utility scores in advanced non-small cell lung cancer. Lung Cancer. 2008;62(3):374–380.
   PubMed Web of Science ®Google Scholar
• Swan IRC, Guy FH, Akeroyd MA. Health-related quality of life before and after management in adults referred to otolaryngology: a prospective national study. Clin Otolaryngol. 2012;37(1):35–43.
   PubMed Web of Science ®Google Scholar
• Curtis KA, Burns A. Unit costs of health & social care 2019; 2019. Available from: https://www.pssru.ac.uk/project-pages/unit-costs/unit-costs-2019/.
   Google Scholar
• NHS. National cost collection for the NHS: 2018/19 National cost collection data 2020; 2020 [cited 2020 Sep 29]. Available from: https://www.england.nhs.uk/national-cost-collection/#ncc1819
   Google Scholar
• Chen Z, Brodie MJ, Liew D, et al. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-Year longitudinal cohort study. JAMA Neurol. 2018;75(3):279–286.
   PubMed Web of Science ®Google Scholar
• Marson A, Burnside G, Appleton R, et al. The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. Lancet. 2021;397(10282):1375–1386.
   PubMed Web of Science ®Google Scholar
• Marson A, Burnside G, Appleton R, et al. The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. Lancet. 2021;397(10282):1363–1374.
   PubMed Web of Science ®Google Scholar
• NHS Business Services Authority. Prescription cost analysis – England, January 2020. PAS; 2020. Available from: https://www.nhsbsa.nhs.uk/sites/default/files/2020-04/PCA%20Jan20.xlsx
   Google Scholar
• British Medical Association and Royal Pharmaceutical Society of Great Britain. UK British National Formulary; 2020. Available from: https://bnf.nice.org.uk/
   Google Scholar
• Boon P, D'Hav M, VanWalleghem P, et al. Direct medical costs of refractory epilepsy incurred by three different treatment modalities: a prospective assessment. Epilepsia. 2002;43(1):96–102.
   PubMed Web of Science ®Google Scholar
• Jennum P, Sabers A, Christensen J, et al. Socioeconomic evaluation of vagus stimulation: a controlled national study. Seizure. 2016;42:15–19.
   PubMed Web of Science ®Google Scholar
• Kopciuch D, Barciszewska A-M, Fliciński J, et al. Economic and clinical evaluation of vagus nerve stimulation therapy. Acta Neurol Scand. 2019;140(4):244–251.
   PubMed Web of Science ®Google Scholar
• Bernstein AL, Barkan H, Hess T. Vagus nerve stimulation therapy for pharmacoresistant epilepsy: effect on health care utilization. Epilepsy Behav. 2007;10(1):134–137.
   PubMed Web of Science ®Google Scholar
• Purser MF, Mladsi DM, Beckman A, et al. Expected budget impact and health outcomes of expanded use of vagus nerve stimulation therapy for drug-resistant epilepsy. Adv Ther. 2018;35(10):1686–1696.
   PubMed Web of Science ®Google Scholar
• Helmers SL, Duh MS, Guerin A, et al. Clinical and economic impact of vagus nerve stimulation therapy in patients with drug-resistant epilepsy. Epilepsy Behav. 2011;22(2):370–375.
   PubMed Web of Science ®Google Scholar
• Majoie MH, Berfelo MW, Aldenkamp AP, et al. Vagus nerve stimulation in children with therapy-resistant epilepsy diagnosed as Lennox-Gastaut syndrome: clinical results, neuropsychological effects, and cost-effectiveness. J Clin Neurophysiol. 2001;18(5):419–428.
   PubMed Web of Science ®Google Scholar
• de Kinderen RJ, Postulart D, Aldenkamp AP, et al. Cost-effectiveness of the ketogenic diet and vagus nerve stimulation for the treatment of children with intractable epilepsy. Epilepsy Res. 2015;110:119–131.
   PubMed Web of Science ®Google Scholar
• Helmers SL, Duh MS, Guerin A, et al. Clinical outcomes, quality of life, and costs associated with implantation of vagus nerve stimulation therapy in pediatric patients with drug-resistant epilepsy. Eur J Paediatr Neurol. 2012;16(5):449–458.
   PubMed Web of Science ®Google Scholar
• Dodrill CB, Morris GL. Effects of vagal nerve stimulation on cognition and quality of life in epilepsy. Epilepsy Behav. 2001;2(1):46–53.
   PubMed Web of Science ®Google Scholar
• Craig D, Rice S, Paton F, et al. Retigabine for the adjunctive treatment of adults with partial-onset seizures in epilepsy with and without secondary generalization: a NICE single technology appraisal. Pharmacoeconomics. 2013;31(2):101–110.
   PubMed Web of Science ®Google Scholar
• Hawkins N, Epstein D, Drummond M, et al. Assessing the cost-effectiveness of new pharmaceuticals in epilepsy in adults: the results of a probabilistic decision model. Med Decis Making. 2005;25(5):493–510.
   PubMed Web of Science ®Google Scholar
• Simoens S, De Naeyer L, Dedeken P. Cost effectiveness of lacosamide in the adjunctive treatment of patients with refractory focal epilepsy in Belgium. CNS Drugs. 2012;26(4):337–350.
   PubMed Web of Science ®Google Scholar
• Vera-Llonch M, Brandenburg NA, Oster G. Cost-effectiveness of add-on therapy with pregabalin in patients with refractory partial epilepsy. Epilepsia. 2008;49(3):431–437.
   PubMed Web of Science ®Google Scholar
• Pathak SJ, Shah VB. Sudden unexpected death in epilepsy. Treasure Island (FL): StatPearls Publishing; 2021.
   Google Scholar